update deskIsrael News

Israel first country to approve medical-cannabis vaporizers

The Israeli Ministry of Health has granted initial approval to VapePod, developed by Kanabo Research.

A demonstration during CannaTech, Israel’s annual medical cannabis innovation conference in Tel Aviv, March 20, 2017. Credit: Miriam Alster/Flash90.
A demonstration during CannaTech, Israel’s annual medical cannabis innovation conference in Tel Aviv, March 20, 2017. Credit: Miriam Alster/Flash90.

Israel has become the world’s first country to approve cannabis vaporizers for medical use.

The Israeli Ministry of Health has granted initial approval to the VapePod vaporizer developed by Kanabo Research, a Tel-Aviv-based medical-cannabis research and development company, according to a report by Israel21c.

Most medical marijuana patients receive the benefits of cannabis from smoking. The approved vaporizer will free users from the detriments of smoking and deliver consistent, accurate dosing in a more effective manner.

“We expect that due to the transition of most of the cannabis consumers to the use of vaporizers, our company is projected to reach $10 million in sales within three years in the Israeli market, while the Israeli cannabis market is expected to reach $100 million in sales within three years,” said Avihu Tamir, co-founder and CEO of Kanabo Research. “The Israeli market is a platform to deliver our technology to global markets in North America and Europe.”

The organization is currently performing pre-clinical trials to treat sleep disorders with VapePod.

You have read 3 articles this month.
Register to receive full access to JNS.

Just before you scroll on...

Israel is at war. JNS is combating the stream of misinformation on Israel with real, honest and factual reporting. In order to deliver this in-depth, unbiased coverage of Israel and the Jewish world, we rely on readers like you. The support you provide allows our journalists to deliver the truth, free from bias and hidden agendas. Can we count on your support? Every contribution, big or small, helps JNS.org remain a trusted source of news you can rely on.

Become a part of our mission by donating today
Topics
Comments
Thank you. You are a loyal JNS Reader.
You have read more than 10 articles this month.
Please register for full access to continue reading and post comments.
Never miss a thing
Get the best stories faster with JNS breaking news updates